Key Points
- CFO Julie Andrews sold 4,873 shares on Jan. 16 at an average price of $14.38 for $70,073.74, reducing her stake to 58,039 shares (a 7.75% decrease) per an SEC filing.
- Orthofix shares opened at $13.85, trade in a 12‑month range of $10.24–$20.48, have a market cap of about $548.5M and a negative trailing PE of -4.57, with 50- and 200-day moving averages near $15.27 and $14.36.
- Institutional ownership is high (89.76%) with firms like Engine Capital increasing positions, and analysts hold a consensus "Moderate Buy" rating with an average target price of $21.50.
Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CFO Julie Andrews sold 4,873 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $14.38, for a total transaction of $70,073.74. Following the completion of the transaction, the chief financial officer directly owned 58,039 shares in the company, valued at approximately $834,600.82. This represents a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Orthofix Medical Trading Up 1.5%
Shares of NASDAQ:OFIX opened at $13.85 on Thursday. Orthofix Medical Inc. has a 12-month low of $10.24 and a 12-month high of $20.48. The stock has a market cap of $548.46 million, a PE ratio of -4.57 and a beta of 0.79. The business has a 50 day moving average of $15.27 and a 200-day moving average of $14.36. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39.
Hedge Funds Weigh In On Orthofix Medical
Several hedge funds and other institutional investors have recently made changes to their positions in the company. AYAL Capital Advisors Ltd raised its holdings in shares of Orthofix Medical by 74.7% during the 2nd quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company's stock worth $10,517,000 after buying an additional 403,433 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Orthofix Medical by 515.6% in the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company's stock valued at $1,312,000 after purchasing an additional 98,552 shares in the last quarter. Gradient Capital Advisors LLC bought a new stake in shares of Orthofix Medical during the 2nd quarter valued at approximately $223,000. Engine Capital Management LP increased its position in Orthofix Medical by 13.6% during the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company's stock worth $47,406,000 after purchasing an additional 510,281 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Orthofix Medical in the 2nd quarter valued at approximately $147,000. 89.76% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
OFIX has been the topic of several recent research reports. Barrington Research increased their price objective on Orthofix Medical from $17.00 to $18.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus began coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They set a "buy" rating and a $22.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Orthofix Medical presently has an average rating of "Moderate Buy" and an average target price of $21.50.
Check Out Our Latest Stock Analysis on Orthofix Medical
Orthofix Medical Company Profile
(
Get Free Report)
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
